Cresco Labs Balance Sheet Health

Financial Health criteria checks 3/6

Cresco Labs has a total shareholder equity of $428.1M and total debt of $411.8M, which brings its debt-to-equity ratio to 96.2%. Its total assets and total liabilities are $1.4B and $930.4M respectively. Cresco Labs's EBIT is $63.2M making its interest coverage ratio 1. It has cash and short-term investments of $103.4M.

Key information

96.2%

Debt to equity ratio

US$411.83m

Debt

Interest coverage ratio1x
CashUS$103.43m
EquityUS$428.07m
Total liabilitiesUS$930.40m
Total assetsUS$1.36b

Recent financial health updates

Recent updates

Cresco Labs Inc. (CSE:CL) Released Earnings Last Week And Analysts Lifted Their Price Target To CA$5.41

Mar 16
Cresco Labs Inc. (CSE:CL) Released Earnings Last Week And Analysts Lifted Their Price Target To CA$5.41

Investors Don't See Light At End Of Cresco Labs Inc.'s (CSE:CL) Tunnel And Push Stock Down 32%

Mar 03
Investors Don't See Light At End Of Cresco Labs Inc.'s (CSE:CL) Tunnel And Push Stock Down 32%

Cresco Labs (CSE:CL) Seems To Be Using A Lot Of Debt

Jan 26
Cresco Labs (CSE:CL) Seems To Be Using A Lot Of Debt

Risks To Shareholder Returns Are Elevated At These Prices For Cresco Labs Inc. (CSE:CL)

Jan 04
Risks To Shareholder Returns Are Elevated At These Prices For Cresco Labs Inc. (CSE:CL)

Is Cresco Labs (CSE:CL) Using Too Much Debt?

Sep 22
Is Cresco Labs (CSE:CL) Using Too Much Debt?

Some Confidence Is Lacking In Cresco Labs Inc. (CSE:CL) As Shares Slide 33%

Aug 11
Some Confidence Is Lacking In Cresco Labs Inc. (CSE:CL) As Shares Slide 33%

Cresco Labs (CSE:CL) Has A Somewhat Strained Balance Sheet

Jan 25
Cresco Labs (CSE:CL) Has A Somewhat Strained Balance Sheet

Are Investors Undervaluing Cresco Labs Inc. (CSE:CL) By 24%?

Dec 13
Are Investors Undervaluing Cresco Labs Inc. (CSE:CL) By 24%?

We Think Cresco Labs (CSE:CL) Is Taking Some Risk With Its Debt

Aug 22
We Think Cresco Labs (CSE:CL) Is Taking Some Risk With Its Debt

Estimating The Intrinsic Value Of Cresco Labs Inc. (CSE:CL)

May 23
Estimating The Intrinsic Value Of Cresco Labs Inc. (CSE:CL)

Cresco Labs Inc. (CSE:CL) Analysts Are Way More Bearish Than They Used To Be

Mar 24
Cresco Labs Inc. (CSE:CL) Analysts Are Way More Bearish Than They Used To Be

Estimating The Fair Value Of Cresco Labs Inc. (CSE:CL)

Feb 02
Estimating The Fair Value Of Cresco Labs Inc. (CSE:CL)

Cresco Labs Inc. (CSE:CL) Shares Could Be 41% Below Their Intrinsic Value Estimate

Oct 27
Cresco Labs Inc. (CSE:CL) Shares Could Be 41% Below Their Intrinsic Value Estimate

Cresco Labs (CSE:CL) Takes On Some Risk With Its Use Of Debt

Oct 06
Cresco Labs (CSE:CL) Takes On Some Risk With Its Use Of Debt

Cresco Labs Inc. (CSE:CL) Just Reported Annual Earnings And Analysts Are Lifting Their Estimates

Mar 27
Cresco Labs Inc. (CSE:CL) Just Reported Annual Earnings And Analysts Are Lifting Their Estimates

Financial Position Analysis

Short Term Liabilities: CL's short term assets ($278.1M) exceed its short term liabilities ($200.2M).

Long Term Liabilities: CL's short term assets ($278.1M) do not cover its long term liabilities ($730.2M).


Debt to Equity History and Analysis

Debt Level: CL's net debt to equity ratio (72%) is considered high.

Reducing Debt: CL's debt to equity ratio has increased from 0% to 96.2% over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: Whilst unprofitable CL has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.

Forecast Cash Runway: CL is unprofitable but has sufficient cash runway for more than 3 years, due to free cash flow being positive and growing by 3.1% per year.


Discover healthy companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.